Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SafiledCriticalEuro Celtique Sa
Publication of GEP20063804BpublicationCriticalpatent/GEP20063804B/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
1. Technical Result Increase in analgetic action. 2. Essence A sustained-release oral dosage form for once-a-day administration comprising: a pharmace¬utically acceptable matrix comprising an analge¬sically effective amount of oxycodone or a pharmaceutically acceptable salt thereof and a sustained release material, said dosage form providing an analgesic effect for at least about 24 hours after oral administration at steady state to human patients; and said dosage form providing a mean C24/Cm oxycodone ratio of 0.6 to 1.0 after steady state oral administration to said patients. 3. Field of Application Medicine.
Composition containing base or coat for moderated release and antagonist of nmda receptor, method for introduction of such nmda antagonist to individual
COMBINATIONS OF PAROXETIN AND 4- (S) - (4-ACETYLPIPERAZIN-1-IL) -2- (R) - (4-fluoro-2-methylphenyl) piperidine-1-carboxylic acid [1- (R) - (3, 5-BIS-TRIFFORMETHYLPHENYL) ETHYL] METHYLAMIDE FOR THE TREATMENT OF DEPRESSION AND / OR ALARM
PHARMACEUTICAL COMPOSITION OF SLOW RELEASE THAT INCLUDES (+) - (2S, 3S) -2- (3-CHLOROPHENYL) -3,5,5-TRIMETHYL-2-MORPHOLINOL AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT